Galapagos NV

GLPG XNAS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

1.8B

Short interest (Apr 30)

2.2%

Net Short (May 07 ): 0.0%

Borrow Fee

1.09%

Available Shares

Price Chart

Company Overview

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Company Info

Exchange: NASDAQ

CIK: 0001421876

Asset Type: ADRC

Market Data

Market Cap: $1,827,325,778

Employees: 452

Status: Active

Short Interest

Current Borrow Fee 1.09%

Range: 0.92% - 1.09%

Available Shares 1M

Range: 1M - 1.4M

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime